Hikma Pharmaceuticals’ Credit Rating Upgraded by S&P

The latest update is out from Hikma Pharmaceuticals ( (GB:HIK) ).

S&P has upgraded Hikma Pharmaceuticals PLC’s long-term issuer credit rating and its $500 million notes to ‘BBB’ from ‘BBB-‘, citing the company’s strong business momentum and stable growth prospects. This upgrade reinforces Hikma’s solid market position and highlights its consistent profitability and cash generation capabilities.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.

Hikma Pharmaceuticals shows robust financial performance with strong revenue and profit growth, complemented by positive corporate events, enhancing its long-term outlook. However, technical indicators suggest caution due to current bearish momentum. The valuation is reasonable, making it attractive for long-term investors, but immediate market weaknesses temper the overall score.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a global pharmaceutical company headquartered in the UK, with operations across North America, the Middle East and North Africa (MENA), and Europe. The company specializes in creating high-quality branded and non-branded generic medicines, leveraging its expertise to transform scientific innovation into accessible healthcare solutions. Hikma is a leading licensing partner and actively invests in innovative health technologies through its venture capital arm.

Average Trading Volume: 562,450

Technical Sentiment Signal: Buy

Current Market Cap: £4.43B

For an in-depth examination of HIK stock, go to TipRanks’ Stock Analysis page.